ライフサイエンスコーパス: dizziness

1 headache, somnolence, dry mouth, nausea, and dizziness).

2 adverse effects of isradipine were edema and dizziness.

3 ance recovery from problems with balance and dizziness.

4 esented with a 7-day history of numbness and dizziness.

5 ded fatigue, diarrhea, asthenia, nausea, and dizziness.

6 and included infections, skin disorders, and dizziness.

7 reatment because of drug-related fatigue and dizziness.

8 ache, dry mouth, constipation, insomnia, and dizziness.

9 OM that is responsible for hearing loss and dizziness.

10 ss-related handicap in patients with chronic dizziness.

11 pregabalin and lorazepam were somnolence and dizziness.

12 ildren with a history of syncope or frequent dizziness.

13 n placebo reported asthenia, somnolence, and dizziness.

14 he symptoms and disabilities associated with dizziness.

15 a headache, nausea, shortness of breath, and dizziness.

16 taxia of over 2 weeks' duration or recurrent dizziness.

17 gnostic testing in syncope, near syncope, or dizziness.

18 nts (77%) and included headache, nausea, and dizziness.

19 heir perceived levels of motion sickness and dizziness.

20 ch as palpitations, shortness of breath, and dizziness.

21 ere the most important predictors of chronic dizziness.

22 symptoms, as well as headaches, fatigue, and dizziness.

23 events were insomnia, diarrhoea, nausea, and dizziness.

24 self-motion sensitivity and visually-induced dizziness.

25 a for the treatment of asthma and poststroke dizziness.

26 nt who presented with fever, sore throat and dizziness.

27 se effects after eltoprazine were nausea and dizziness.

28 ciated with higher incidences of fatigue and dizziness.

29 1.6 [1.5-1.7]), memory loss (1.8 [1.6-2.0]), dizziness (1.7 [1.6-1.8]), and vaginal discharge (1.8 [1

30 .51), urinary dysfunction (1.96, 1.34-2.80), dizziness (1.99, 1.67-2.37), fatigue (1.56, 1.27-1.91),

31 adache (48 [46.6%]), confusion (15 [14.6%]), dizziness (11 [10.7%]), and nausea (8 [7.8%]).

32 18 [7%]), headache (16 [3%] vs 12 [5%]), and dizziness (12 [2%] vs eight [3%]).

33 %]), peripheral edema (15 [23.8%] vs 0), and dizziness (14 [22.2%] vs 0).

34 laise (88%), myalgia (57%), cough (25%), and dizziness (14%).

35 unction (21% vs 20%), headache (26% vs 10%), dizziness (15% vs 10%), and hypotension (8% vs 2%).

36 01), vomiting (11.3% vs. 7.1%, P=0.008), and dizziness (15.1% vs. 11.0%, P=0.03) than the placebo gro

37 ent adverse events were hypotension (17.6%), dizziness (16.8%), hyperkalemia (13.2%), and worsening k

38 any severe (3%), headache (4%), nausea (2%), dizziness (2%), nasopharyngitis (1%), and injection site

39 more frequently in the gabapentin group were dizziness (20 [24%] in the gabapentin group vs 4 [4.9%]

40 ents (placebo 79/121 (65.3%)), most commonly dizziness (23.1%), somnolence (16.5%), headache (14.0%).

41 than with EFV/FTC/TDF (72/348 vs 48/352) and dizziness (23/348 vs 86/352), abnormal dreams (53/348 vs

42 OR], 0.71 [95% CI, 0.42-1.21]), unsteadiness/dizziness (29/151 [19.2%] vs 11/89 [12.4%] attacks; OR,

43 oea (3.9%, 6.8%), headache (5.9%, 6.8%), and dizziness (3.0%, 6.2%).

44 [5%], 29 [6%], and 102 [10%], respectively), dizziness (31 [3%], 36 [7%], 99 [10%], respectively), an

45 The most common clinical indication was dizziness (41.18%).

46 of sleep (47 [92%] vs 39 [71%]), orthostatic dizziness (42 [78%] vs 46 [81%]), depression (43 [80%] v

47 ncope; 7.5 for local site reactions; 6.8 for dizziness; 5.0 for nausea; 4.1 for headache; 3.1 for hyp

48 8 [2.5%]; and placebo, 10 of 499 [2.0%]) and dizziness (50 mg, 7 of 488 [1.4%]; 25 mg, 10 of 478 [2.1

49 r syndrome (77%, 0%, and 0%; p < 0.0001) and dizziness (50%, 0%, and 0%; p < 0.0001).

50 A total of 805 454 individuals with dizziness (502 055 women [62%]; median age, 52 years [ra

51 261 participants (24%) reported dizziness; 56% of dizzy persons described several sensat

52 nsient xenon-related symptoms, most commonly dizziness (59%), paresthesia (34%), euphoria (30%), and

53 ypertension (97 [32%]), headache (78 [26%]), dizziness (61 [20%]), and fatigue (56 [19%]).

54 s 6 [2%]), rash (111 [32%] vs 40 [12%]), and dizziness (63 [18%] vs 35 [10%]) than did those in the p

55 Patients reported nausea (95%), dizziness (72%), abdominal cramps (58%), headache (52%),

56 n placebo and two on seladelpar 200 mg), and dizziness (8%; one patient on placebo and two on seladel

57 recipients had significantly lower rates of dizziness (8.8% vs 37.1%), sleep disorders/disturbances

58 ceived ondonsetron than granisetron reported dizziness (9.6% v 5.4%, respectively; P = .011) and abno

59 There were more dizziness (9.9% vs 1.1%), hypotension (8.8% vs 0%), and

60 most common condition is chronic subjective dizziness; a refinement of earlier concepts of psychogen

61 The most common AEs reported were headache, dizziness, abdominal pain, fever, nausea, and fatigue.

62 issociation, nausea, vertigo, dysgeusia, and dizziness) all were observed more frequently in the eske

63 ernative therapies for chronic and recurrent dizziness also merit investigation.

64 edness, skin swelling, nausea, vomiting, and dizziness, among others.

65 ompared to the control group (29.6% referred dizziness and 23.9% vomiting after the first IPTp-MQ adm

66 th agents were well tolerated, although more dizziness and abnormal vision were reported with ondanse

67 le drug related AEs reported were dry mouth, dizziness and anxiety in one patient and hypotension in

68 vestibular disorders experience symptoms of dizziness and balance dysfunction, resulting in falls, a

69 Dizziness and blackouts were reported by 40.0% (318/796)

70 act of falls, and the overlap between falls, dizziness and blackouts, in a population-based sample of

71 e was marked overlap in the report of falls, dizziness and blackouts.

72 cal orthostatic symptoms such as orthostatic dizziness and blurred vision, and atypical symptoms like

73 near-vision tasks and in some cases causing dizziness and discomfort.

74 Ataxia, causing imbalance, dizziness and falls, is a leading cause of neurological

75 AMS, characterized by headache, nausea, dizziness and fatigue, is usually benign and self-limiti

76 sical therapists have been shown to decrease dizziness and improve postural control.

77 Dizziness and light-headedness were more common in the l

78 ome, and dysautonomias also cause persistent dizziness and may be misdiagnosed or malingering or psyc

79 nly approved antagonist for epilepsy, induce dizziness and motor impairment.

80 with ABT-418 was relatively well tolerated; dizziness and nausea were the most frequently reported a

81 ws the often-enigmatic relationships between dizziness and psychiatric symptoms.

82 Dizziness and renal insufficiency was observed more freq

83 Dizziness and somnolence were the most frequent adverse

84 uring the study, although two reported acute dizziness and were withdrawn from the study.

85 em effects of opioids including sedation and dizziness, and 2) osteoporosis caused by chronic opioid-

86 partment with new-onset bitemporal headache, dizziness, and bilateral lower extremity weakness for 1

87 lus placebo group were somnolence, sedation, dizziness, and constipation.

88 She also reported having fatigue, dizziness, and decreased appetite.

89 rial withdrawals and adverse events of rash, dizziness, and dental discoloration were more frequent a

90 Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperid

91 suffered from abdominal pain, constipation, dizziness, and dry mouth.

92 were nausea, fatigue, neutropenia, alopecia, dizziness, and dyspnea.

93 s sham cognitive rehabilitation group (pain, dizziness, and falls), two in the cognitive rehabilitati

94 quently reported adverse events were nausea, dizziness, and headache.

95 Fatigue, dizziness, and hypertension were more commonly reported

96 Adverse experiences included nausea, dizziness, and insomnia.

97 ide and 22% receiving placebo; constipation, dizziness, and malaise were more frequent with thalidomi

98 ents reported with lorcaserin were headache, dizziness, and nausea.

99 opioid-induced constipation (OIC), sedation, dizziness, and nausea.

100 events in the treatment group were headache, dizziness, and nausea.

101 n cause neurological symptoms such as fever, dizziness, and nausea.

102 morbidity, including hearing loss, tinnitus, dizziness, and possibly even death from brainstem compre

103 g, tiredness, breathlessness, feeling faint, dizziness, and restless legs, especially among men [for

104 f the placebo group) were nausea, akathisia, dizziness, and sedation.

105 ted by side effects, particularly headaches, dizziness, and skin irritation.

106 events (including abnormal dreams, anxiety, dizziness, and somnolence) were significantly more commo

107 AEs of nausea, headache, constipation, dizziness, and somnolence, each occurred in >=10% of pat

108 lozapine experienced more excess salivation, dizziness, and sweating and less dry mouth and decreased

109 Various disease entities may cause dizziness, and the reported frequency of specific diagno

110 ith a 1-week history of intermittent emesis, dizziness, and vertigo and a 1-day history of wobbly gai

111 ith a 1-week history of intermittent emesis, dizziness, and vertigo and a 1-day history of wobbly gai

112 Diarrhea, dizziness, and vomiting were more common in the difelike

113 ts were fatigue, headache, nausea, diarrhea, dizziness, and vomiting.

114 rred for at least 1 month; manifestations of dizziness; and predisposing demographic, medical, neurol

115 l group had a small increase in frequency of dizziness, anemia, and infections.

116 s of adverse effects (eg, nausea, dry mouth, dizziness, anxiety), whereas the acupuncture group exper

117 s (phase 1b study: hepatic enzyme increased, dizziness, aphthous ulcer, arthralgia, arthritis, increa

118 Anxiety and dizziness are co-morbid symptoms in a larger percentage

119 As neck disturbances combined with dizziness are commonly encountered in the clinic, the la

120 l illnesses that masquerade as 'psychogenic' dizziness are examined.

121 The subjects rated their dizziness at each phase.

122 t, in the hemizygote group; and memory loss, dizziness, ataxia, hemiparesis, loss of consciousness an

123 Somnolence, dizziness, ataxia, peripheral edema, and infection were

124 ous symptoms like chest discomfort, fatigue, dizziness, atrial fibrillation, and hypotension.

125 he physiological parameters present during a dizziness attack.

126 d be wary of diagnosing a cervical cause for dizziness based on an actual history of cervical spondyl

127 e misdiagnosed or malingering or psychogenic dizziness because they often present with comorbid psych

128 eatening illnesses are rare in patients with dizziness, but many have serious functional impairment.

129 Classification of dizziness by subtype (vertigo, presyncope, disequilibriu

130 tervention, rashes, subjective complaints of dizziness by the patient, and emergence reactions to ket

131 Dizziness can be difficult to diagnose, particularly in

132 p for 1 year unless they were diagnosed with dizziness, censored by death, or withdrew from the healt

133 logic disorder of persistent non-vertiginous dizziness, chronic subjective dizziness (CSD) arises uns

134 ral vestibular disorders seen in specialized dizziness clinics.

135 ent owing to malaise, headache, and moderate dizziness (Common Terminology Criteria for Adverse Event

136 DLTs were increased ALT/AST (n = 1), dizziness, confusion, and sensory disturbances (n = 2).

137 Side-effects include dizziness, constipation, nausea, and the potential for p

138 , psychological, and medication-related) and dizziness, coupled with the multiplicity of sensations a

139 on-vertiginous dizziness, chronic subjective dizziness (CSD) arises unsteadily by psychological and p

140 ear of falling (FoF), and chronic subjective dizziness (CSD).

141 n-participant changes showed improvements in dizziness (DHI, -36; 95% CI, -55 to -18), vestibular dis

142 th a fatal outcome included fever, weakness, dizziness, diarrhea, and elevated levels of blood urea n

143 tly reported adverse events for ABT-126 were dizziness, diarrhea, and fatigue (all <8% incidence).

144 f 15 patients for each event), and headache, dizziness, diarrhoea, and vomiting were the most frequen

145 ng order of frequency): hemiparesis, vertigo/dizziness, diplopia, dysarthria, nystagmus, nausea/vomit

146 eported spontaneous and provoked symptoms of dizziness, dizziness-related quality of life, and object

147 Dizziness, drowsiness, and visual disturbances were more

148 ide effects in dental outpatients, including dizziness, drowsiness, psychomotor impairment, nausea/vo

149 Somnolence, dizziness, dry mouth, and weight gain occurred significa

150 Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, eupho

151 d groups compared with placebo were anxiety, dizziness, dyspnoea, increased alanine aminotransferase,

152 ics included anemia, anorexia, constipation, dizziness, elevated liver function test results, fever,

153 history of double vision, soft headaches and dizziness episodes.

154 Patient bioeffects such as vertigo, dizziness, false feelings of motion, nausea, nystagmus,

155 the 1991 Gulf War, such as chronic diarrhea, dizziness, fatigue, and sexual dysfunction, are due to c

156 is a rare disorder that leads to paroxysmal dizziness, fatigue, and syncope because of a temporarily

157 g because of adverse events, most frequently dizziness, fatigue, headache, and edema.

158 main side-effects were problems of balance, dizziness, feeling faint, nausea, and/or vomiting shortl

159 lingual film), somnolence (seven [13%]), and dizziness (five [9%]).

160 participants reported significantly greater dizziness following nicotine, and greater pleasant subje

161 roup; eight [13%] in the 16-week group), and dizziness (four [7%] in the 12-week group; nine [15%] in

162 A total of 805 454 patients presented for dizziness from 2006 through 2015 (median [range] age, 52

163 Change in scores on the Dizziness Handicap Inventory (DHI), the Activities-Speci

164 Baseline dizziness was measured using the Dizziness Handicap Inventory (DHI).

165 The finding of mild postural dizziness has no proven value.

166 a reduction in belching and bloating and in dizziness, headache and muscle cramps, although the decr

167 he most common adverse effects were fatigue, dizziness, headache, and confusion.

168 nces, breast tenderness, abdominal cramping, dizziness, headache, and mood changes.

169 with at least one associated symptom (pains, dizziness, headache, sleep disturbance, inability to rel

170 ; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyperhidrosis, and palpi

171 e events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more com

172 In patients without chronic kidney disease, dizziness, hypokalaemia, and hypotension were more frequ

173 , headache in 14 (50%), malaise in 13 (46%), dizziness in nine (32%), myalgia in four (14%), and chil

174 apies: we observed a significant increase in dizziness in the P-A pathway, nausea in the D-P pathway,

175 to use of emergency contraception; a case of dizziness in the ulipristal acetate group and a molar pr

176 common treatment-related adverse events were dizziness (in 58% of the patients), dysgeusia (in 50%),

177 ents), headache (in 80%), weakness (in 66%), dizziness (in 60%), diarrhea (in 51%), abdominal pain (i

178 ea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients).

179 atients with diabetes) and falling or severe dizziness (in patients without diabetes) were most frequ

180 se (in 13 [19%] of 67 patients), followed by dizziness (in six [9%] patients).

181 diazepine-like side effects (e.g., sedation, dizziness) in ocinaplon-treated patients did not differ

182 In the primary care setting, dizziness increases in frequency as a presenting complai

183 r-function tests, fatigue, nausea, headache, dizziness, insomnia, pruritus, rash, and vomiting.

184 veloped state of the empirical literature on dizziness, investigators would benefit from use of consi

185 Dizziness is a common condition that is responsible for

186 Vestibular rehabilitation for dizziness is a simple treatment that may be suitable for

187 Dizziness is a very common disorder and probably the eas

188 Dizziness is a very common symptom and is usually manage

189 Chronic subjective dizziness is consistent with advancing research on anxie

190 zation to the common notion of 'psychogenic' dizziness is presented.

191 Dizziness is prevalent in all adult populations, causing

192 ange (> or =30 beats/min) or severe postural dizziness is required to clinically diagnose hypovolemia

193 nce is mounting that diagnosing and treating dizziness is very important in this patient group.

194 ntify fear avoidance beliefs in persons with dizziness, it was considered too long for clinical use.

195 levated supine systolic BP before breakfast, dizziness/light-headedness on standing, male sex, medica

196 participant in the placebo group (headache, dizziness, lightheadedness, and chronic abdominal pain).

197 Fifty-one cases (48%) included dizziness, lightheadedness, or a feeling of disequilibri

198 Dizziness/loss of balance was the most frequently report

199 ose-related nausea (<or=28% of patients) and dizziness (<or=18% of patients) tended to resolve with c

200 on a soldier with relapsing fever, headache, dizziness, lumbago, and shin pain.

201 ons and triggering activities, suggests that dizziness may be a geriatric syndrome, similar to deliri

202 Smaller studies noted that initial dizziness may predict PCS.

203 algia, myalgia, malaise, pruritus, headache, dizziness, metallic taste, visual disturbance, circumora

204 Dizziness might be better considered a geriatric syndrom

205 ts were also more likely to have a headache, dizziness, myalgias, abdominal pain, anorexia, leukopeni

206 s requiring treatment (n = 3), rash (n = 2), dizziness (n = 1), wheezing (n = 1), and emergence react

207 Severe AEs included vomiting (n = 32), dizziness (n = 16), headache (n = 11), and convulsions (

208 n=2 [5%]), insomnia (n=1 [2%]), tinnitus and dizziness (n=1 [2%]), and thrombocytopenia (n=1 [2%]).

209 adverse events in the rasagiline group were dizziness (n=10 [12%]), peripheral oedema (n=9 [11%]), u

210 %]), infusion-related reaction (n=20 [43%]), dizziness (n=17 [37%]), nausea (n=17 [37%]), and cough (

211 ith common and non-specific symptoms such as dizziness, nausea and vomiting, unsteady gait, and heada

212 ted symptoms five days later) were headache, dizziness, nausea, and drowsiness.

213 events in the SAGE-217 group were headache, dizziness, nausea, and somnolence.

214 erse events such as asthenia, poor appetite, dizziness, nausea, and vomiting occurred significantly m

215 s included constipation, fatigue, dry mouth, dizziness, nausea, anorexia, arrhythmia, headaches, skin

216 A case (n = 107) was defined as dizziness, nausea, or vomiting occurring in a person who

217 Dizziness, nausea, somnolence, diplopia, fatigue, and ra

218 Psychiatric causes of dizziness, neuro-otologic causes of anxiety, underrecogn

219 ectile dysfunction, urinary dysfunction, and dizziness), neuropsychiatric disturbances (memory proble

220 g headache (19 [4%] vs 11 [3%] patients) and dizziness (nine [2%] vs seven [2%] patients).

221 Dizziness, nystagmus, phosphenes, and head ringing were

222 DM/Q was well tolerated; only dizziness occurred with greater frequency than with plac

223 Adverse events included dizziness (omecamtiv mecarbil: 4.9%, placebo: 5.5%), fat

224 ea (three [4%], 9 [11%], and ten [12%]), and dizziness (one [1%], four [5%], and 11 [13%]).

225 The body's failure to do so can lead to dizziness or even fainting.

226 locomotor training had a higher frequency of dizziness or faintness during treatment (P=0.008).

227 tide and three who received placebo reported dizziness or headache.

228 Side effects from enalapril included dizziness or hypotension (22% v 3% in the placebo group;

229 sitated stopping the vehicle, 22 percent had dizziness or palpitations that did not necessitate stopp

230 rcent had a syncopal episode, 11 percent had dizziness or palpitations that necessitated stopping the

231 sore throat (OR = 4.66; 95% CI: 2.89, 7.51), dizziness (OR = 4.21; 95% CI: 2.69, 6.58), and wheezing

232 medium effects over placebo for unsteadiness/dizziness (OR, 2.65) and motion sensitivity (OR, 3.58).

233 reactive protein at 1 year; fewer headaches, dizziness, or cramps; and shorter postdialysis recovery

234 ld man was seen with progressively worsening dizziness over 10 months.

235 renz (31% [104]; p<0.0001), as were rash and dizziness (p<0.0001 for both) and increases in lipid lev

236 delirium and cognitive dysfunction, fatigue, dizziness, pain, and gastrointestinal dysfunction) after

237 al-psychiatric conditions that cause chronic dizziness, permitting greater diagnostic precision and i

238 efinement of earlier concepts of psychogenic dizziness, phobic postural vertigo, and space-motion pho

239 rgency departments (EDs), most patients with dizziness present to outpatient clinics.

240 e risk of stroke after presumed nonstroke ED dizziness presentations is very low, supporting a nonstr

241 serious concern in emergency department (ED) dizziness presentations.

242 lish stroke risk after presumed nonstroke ED dizziness presentations.

243 by a myriad of symptoms, including anxiety, dizziness, presyncope, and syncope.

244 physical findings are either severe postural dizziness (preventing measurement of upright vital signs

245 In the community, the prevalence of dizziness ranges from 1.8% in young adults to more than

246 e improves symptoms, postural stability, and dizziness-related handicap in patients with chronic dizz

247 ntaneous and provoked symptoms of dizziness, dizziness-related quality of life, and objective measure

248 .79), anxiety (RR, 2.27; 95% CI, 1.11-4.64), dizziness (RR, 5.81; 95% CI, 1.02-33.03), and elevated b

249 l tolerated, but asthenia, fatigue, vertigo, dizziness, sense of imbalance, and loss of concentration

250 oembolism, fatigue, depressed consciousness, dizziness, sensory neuropathy, tremor, constipation, dys

251 The experience is one of rocking dizziness similar to when the individual was originally

252 ]), influenza-like illness (seven [9%]), and dizziness (six [8%]); the most frequent adverse events c

253 adverse events were CNS-related and included dizziness, somnolence and paraesthesia.

254 hasia (each 9%) and tremor, speech disorder, dizziness, somnolence, and disorientation (each 4%).

255 Paroxysmal dizziness spells (PDS), a unique LGI1-IgG accompaniment

256 l manifestations, and stereotypic paroxysmal dizziness spells are common with LGI1-IgG.

257 tral valve presented with a 3-day history of dizziness, subjective fever, and chills.

258 conditions that present with non-vertiginous dizziness, subjective imbalance, and psychiatric symptom

259 Survey (NHIS), which included a Balance and Dizziness Supplement, and questions about cognitive func

260 from use of consistent criteria to describe dizziness symptoms and establish diagnoses.

261 ercept than with placebo included epistaxis, dizziness, telangiectasia, increased hemoglobin levels,

262 ction in flow rates and greater increases in dizziness than the normal comparison subjects.

263 opathies, problems with taste and smell, and dizziness that accompanies erratic heart rates and sever

264 Episodes of dizziness that occurred for at least 1 month; manifestat

265 gical symptoms, such as fatigue, nausea, and dizziness, the implications for brain structure are not

266 In previous studies of dizziness, the prevalence of specific causes has varied

267 Among adults who present with dizziness, there is a critical need to identify and deim

268 dults who present for clinical evaluation of dizziness, there is a critical need to identify interven

269 treatment-related were rash (four [5%]) and dizziness (three [4%]).

270 n runs a spectrum, ranging from headache and dizziness to coma and death, with a mortality rate rangi

271 nd evolved from complaints of somnolence and dizziness, to more pronounced signs and symptoms of cere

272 most common drug-related adverse events were dizziness, tremor, somnolence, headache, nausea, and ras

273 adverse events in the brexanolone group were dizziness (two patients in the brexanolone group vs thre

274 senting to EDs in Nueces County, Texas, with dizziness, vertigo, or imbalance were identified, exclud

275 ade 3 or higher were neutropenia (n = 2) and dizziness/vertigo (n = 1).

276 Headache, constipation, dizziness, vomiting, and dry mouth were also more freque

277 lacebo group, included nausea, constipation, dizziness, vomiting, somnolence, fatigue, and sedation.

278 roblems of visually induced unsteadiness and dizziness (VUD, also known as visual vertigo), fear of f

279 The adjusted relative risk for dizziness was 1.38 (CI, 1.27 to 1.49) for each additiona

280 The incidence of hypotension or dizziness was higher in groups that received the polypil

281 -cause mortality for adults with symptomatic dizziness was higher than for those without (45.6% vs 27

282 Baseline dizziness was measured using the Dizziness Handicap Inve

283 Dizziness was more common in the pregabalin group than i

284 One serious adverse event (dizziness) was rated as possibly related to MK-869.

285 ve risks for characteristics associated with dizziness were 1.69 (95% CI, 1.24 to 2.30) for anxiety,

286 Pruritus, headache, nausea, rash, and dizziness were higher with TVR plus PEG-IFN-alpha2a-riba

287 Muscle weakness and dizziness were more common in the combined-therapy group

288 similar across groups, although diarrhea and dizziness were more frequent in the febuxostat 240 mg gr

289 Mucositis, anorexia, and dizziness were more prevalent in the rotating arm during

290 Headache, anxiety, dissociation, nausea, and dizziness were the most common (>/=20%) treatment-emerge

291 Somnolence, nausea, and dizziness were the most common side effects associated w

292 ic disorder, in which panic symptoms (e.g., "dizziness") were primed by panic triggers (e.g., "elevat

293 tive symptoms (nausea, throat tightness, and dizziness) were prevalent later in life.

294 , such as shortness of breath, headache, and dizziness, were reported in 48 subjects (11.1% of studie

295 Vertigo is a subtype of dizziness, which results from an imbalance within the ve

296 The most common adverse event was dizziness, which was mostly transient and of mild intens

297 rse events were injection-site reactions and dizziness, which were self-limited and without sequelae.

298 170 adult patients with chronic dizziness who were randomly assigned to vestibular rehab

299 terized by brief attacks of unsteadiness and dizziness with persistent myokymia.

300 Adverse effects included somnolence and dizziness with TCAs, SNRIs, and anticonvulsants; xerosto